Abstract The HER2 gene is overexpressed in 15-20 % of all breast cancers. With the advent of HER2-directed therapies, HER2 overexpression is no longer considered an adverse prognostic factor. Despite significant improvements in clinical outcomes with the use of trastuzumab [herceptin (H)], women aged [65 years remain underrepresented in most clinical trials. Cardiac safety in the elderly woman is a major concern because of pre-existing comorbidities. However, many studies suggest that elderly patients with HER2-positive disease derive the same benefit from trastuzumab as do their younger counterparts in both adjuvant and metastatic settings. Data are limited guiding safety and efficacy of other HER2 inhibitors such as pertuzumab and trastuzumab emtansine in elderly patients; however, in general, these drugs have a favorable toxicity profile.
Introduction
HER2 protein is overexpressed in 15-20 % of all breast cancers [1] [2] [3] [4] [5] . However, some studies do report the incidence to be slightly lower in the elderly population [6] . HER2 positivity is defined at an immunohistochemical (IHC) score of C3 or fluorescent in situ hybridization (FISH) positivity (ratio of HER2:CEP17 C2). HER2 overexpression was historically considered a predictor of poor clinical outcome [7, 8] . However, with the advent of specific HER2-directed therapies, there have been & Stuart M. Lichtman lichtmas@mskcc.org significant improvements in outcomes of HER2-positive breast cancer. HER2-directed therapy in combination with chemotherapy has become the standard of care for HER2-overexpressing breast cancer. However, in elderly populations, there is a concern for increasing toxicity, especially cardiotoxicity, when these patients also receive anthracycline-based chemotherapy regimens.
In this article, we discuss the benefits of the addition of HER2-directed therapy in elderly patients in neoadjuvant, adjuvant, and metastatic settings. We also discuss the toxicity of HER2-directed therapy, particularly cardiac toxicity, in this age group.
Trastuzumab
Eight large clinical trials have demonstrated improvement of both progression-free survival (PFS) and overall survival (OS) when trastuzumab is added to chemotherapy in the adjuvant setting [9] [10] [11] [12] [13] [14] [15] . Patients aged [60 years were under-represented in these trials. In two of these trials, NSABP-31 (National Surgical Adjuvant Breast and Bowel Project-31) and N9831 (Figs. 1, 2 ), approximately 16 % of the patients were aged C60 years. NSABP-31 compared four cycles of adjuvant doxorubicin (A) and cyclophosphamide (C) followed by four cycles of 3-weekly paclitaxel (T) with AC followed by concomitant paclitaxel and trastuzumab. Trastuzumab was continued for a total of 52 weeks. N9831 was a threearm study: AC followed by 12 cycles of weekly T (arm A); AC ? T followed by 52 weeks of trastuzumab (arm B); and AC ? T with concomitant trastuzumab, which was continued for 52 weeks (arm C). Arm B was subsequently excluded from final analysis. In the joint analysis of these two trials, there was a statistically significant improvement in the disease-free survival (DFS) (3- [16] . In a recently published trial, patients with stage I HER2-positive breast cancer with the primary tumor measuring up to 3 cm in the greatest dimension (patients with micrometastases in a single axillary lymph node were eligible if an axillary dissection was completed without further evidence of lymph node involvement), were treated with paclitaxel for 12 weeks combined with trastuzumab, which was then continued for a total of 52 weeks. The DFS after 3 years of follow-up was 98.7 %; 33.7 % of patients in this trial were aged [60 years. Although follow-up was short, this trial demonstrates a high efficacy of the paclitaxel-trastuzumab combination in stage I patients in whom anthracycline-based therapies may be safely avoided [17] .
In the pivotal trastuzumab phase III trial, 469 women with HER2-positive metastatic breast cancer were randomized to standard chemotherapy alone (doxorubicin or epirubicin in combination with cyclophosphamide) versus chemotherapy plus trastuzumab. The addition of trastuzumab to chemotherapy was associated with longer time to progression (TTP; 7.4 vs. 4.6 months, p \ 0.001), a higher overall response rate (ORR: 50 vs. 32 %, p \ 0.001), a longer duration of response (9.1 vs. 6.1 months, p \ 0.001), a lower rate of death at 1 year (22 vs. 33 %, p = 0.008), a longer OS (25.1 vs. 20.3 months, p = 0.01), and a 20 % reduction in the risk of mortality [18] . Based on this trial, trastuzumab was approved in combination with paclitaxel for first-line treatment of HER2-positive metastatic breast cancer in 1998. Other combinations shown to be effective in this setting include docetaxel plus trastuzumab [19, 20] and vinorelbine plus trastuzumab [21] . Although efficacious, anthracycline/trastuzumab combinations are not indicated outside clinical trials in MBC due to an increased risk of cardiac toxicity [22] .
Cardiac Safety of Trastuzumab
HER2 signaling is involved in myocardial hemostasis and therefore HER2 blockade is associated with myocardial injury [23] . Cardiac dysfunction from trastuzumab is often considered reversible and not associated with higher cumulative doses of trastuzumab. In contrast, anthracyclines cause oxidative damage, leading to myocyte cell death, and often lead to irreversible cardiac injury. Myocardial injury from anthracyclines is dose dependent and cumulative in nature [24] [25] [26] [27] . Recent studies have suggested that ERB-2 (HER2) expression upregulates anti-oxidant enzymes, reduces basal levels of anti-oxidant species in the myocardium, and prevents free-radical injury induced by doxorubicin [28] [29] [30] . Therefore, HER2 blockade predisposes the heart to anthracycline-induced damage [31] .
No standard guidelines exist on the management of trastuzumab cardiotoxicity, since it is not systematically treated in all circumstances. However, beta-blockers (BBs) and angiotensin-converting enzyme (ACE) inhibitors have some role in management. In the setting of BB and ACE inhibitors, patients can usually be re-challenged with trastuzumab without worsening heart failure [29] . In recent years, the reversibility of trastuzumab cardiotoxicity has been debated, especially when used with anthracyclines. In a study performed by a cardiac review and evaluation committee, 82 of 83 patients treated with trastuzumabbased therapies and who developed cardiac dysfunction were treated with heart failure therapies such an ACE inhibitor and BBs. Treatment outcomes differed in the group treated with trastuzumab and AC versus that treated with trastuzumab and paclitaxel. Eight of 39 patients in the herceptin (H) ? AC group continued to display significant cardiac functional impairment (New York Heart Association [NYHA] class III) following medical therapy, while all 12 patients treated with trastuzumab ? paclitaxel recovered. Moreover, in heavily pretreated patients receiving single-agent trastuzumab, less impressive recovery in cardiac function is observed [23] .
In the cardiac safety analysis of the HERA (HERceptin Adjuvant) trial, which compared 1 or 2 years of trastuzumab with observation alone, the incidence of significant cardiac events leading to discontinuation of trastuzumab was 5.2 % in the group treated with trastuzumab for 1 year and 9.4 % in the group treated with trastuzumab for 2 years. The incidence of severe congestive heart failure (CHF) was 0.8 % in the trastuzumab group versus 0 % in the observation group. The incidence of significant decline in left ventricular ejection fraction (LVEF) was 4.1 versus 0.9 %. Only 15 % of the patients enrolled in this trial were aged [60 years [32] .
In a retrospective review analysis of seven phase II and III trials with trastuzumab, the incidence of cardiotoxicity was found to be 2 % with trastuzumab alone, 2-13 % when trastuzumab was combined with paclitaxel, and 27 % when combined with anthracyclines. Trastuzumab-related toxicity usually improved with standard heart failure management in most cases [18, 23, 28, [33] [34] [35] [36] . The rate of symptomatic CHF ranges from 1.5 to 5.1 %, while the rates of asymptomatic declines in LVEF ranges from 3.5-19 % in most studies [11, 15, [37] [38] [39] [40] . However, in the SEER (Surveillance, Epidemiology and End Results) and Texas Cancer Registry medicare database analysis of 2203 elderly patients (aged [66 years) treated with trastuzumab, CHF rates were found to be 29.4 % in trastuzumab users compared with 18.9 % in non-trastuzumab users, much higher in the above-mentioned studies that mostly excluded elderly patients. Older age ([80 years), hypertension, coronary artery disease, and weekly administration of trastuzumab were the risk factors associated with CHF in this study [41] . In another larger series of 2046 trastuzumab users, the incidence of cardiotoxicity was 0.2 % in women aged \50 years, while it was 10 % in women aged [70 years, irrespective of cardiovascular status (HR for cardiac toxicity was 11.3 for women aged[70 years; 95 % CI 3.5-36.6) [42] .
In a small trial of 59 elderly (aged [70 years, median age 76) HER2-positive patients, there were ten cases of cardiotoxicity; seven of ten patients had received concomitant chemotherapy with trastuzumab. There was only one case of symptomatic CHF. Hypertension and obesity were risk factors for cardiotoxicity in this trial [43] .
However, in the paclitaxel-trastuzumab study, only two patients (0.5 %; 95 % CI 0.1-1.8) had grade 3 systolic dysfunction during active therapy, which resolved after discontinuation of trastuzumab. Clinically significant asymptomatic decline in function was seen in 13 patients (3.2 %; 95 % CI 1.7-5.4) [17] . This implies that higher cardiac toxicity observed in the trastuzumab subgroup in the HERA, NSABP-31, and N9831 trials is likely secondary to the concomitant administration of anthracyclines.
Guarneri et al. [44] looked at 218 patients who were treated with trastuzumab for metastatic breast cancer at MD Anderson Cancer Center for C1 year; 20 % of these patients were aged [60 years. The older age group did not have proportionally greater cardiac toxicity in this study. Of all patients who suffered from a cardiac event, only 16.3 % were aged [60 years [44] .
There is increasing evidence that trastuzumab-based chemotherapy, when chosen appropriately, is safe and efficacious, even in elderly populations. Cardiotoxicity is the most common reason for potentially life-saving anti-HER2 therapy being withheld from patients. In a retrospective review of 573 patients, 92 (16 %) of whom developed treatment-induced cardiotoxicity (74 patients were asymptomatic), treatment was continued in 31 patients (all asymptomatic with ejection fraction [EF] [50 %). None of these patients subsequently developed heart failure [45] .
Pertuzumab
Pertuzumab is a humanized monoclonal antibody that targets the extracellular dimerization domain of the HER2 receptor. It disrupts formation of HER2 homodimers as well as HER1/HER2 and HER2/HER3 heterodimers, thus blocking intracellular signaling through the mitogen-activated protein kinase (MAPK) pathway and the phosphotidyl-inositol-3 (PI3K) pathway, ultimately causing cell cycle arrest and apoptosis [46] .
It was first studied in metastatic HER2-positive breast cancer that had progressed on trastuzumab only; it was found to be well-tolerated, with LVEF remaining close to baseline when combined with trastuzumab. Objective responses were seen in 24.2 % of patients, while stable disease was achieved in 25.8 % [47] .
It is US FDA approved for use in combination with trastuzumab and taxane as a first-line therapy in the metastatic setting as well as in the neoadjuvant setting.
In the phase III CLEOPATRA trial, the combination of pertuzumab, trastuzumab, and docetaxel was compared with placebo, trastuzumab, and docetaxel in metastatic HER2-positive breast cancer [48] . Of 808 patients enrolled, 129 were aged C65 years. The results of a subgroup analysis of the CLEOPATRA trial revealed that these elderly patients had PFS benefit when pertuzumab was added (PFS 21.5 vs. 10.4 months; HR 0.52, 95 % CI 0.31-0.86). However, the incidence of diarrhea, fatigue, dysgeusia, decreased appetite, asthenia, and vomiting is more frequent in the older subgroup. Age had no statistically significant association with left ventricular systolic dysfunction in this trial. Given the excellent efficacy and favorable toxicity profile of pertuzumab and trastuzumab in combination with taxanes, it should be considered a firstline treatment for metastatic disease in the elderly population [49] .
The cardiac safety profile of pertuzumab has been found to be favorable in clinical trials [50] . The cardiac safety of neoadjuvant trastuzumab plus pertuzumab in combination with both anthracycline and non-anthracycline chemotherapy was tested in the phase II TRYPHAENA study. This was a three-arm study randomizing patients to the following three arms: 5-fluorouracil epirubicin cytoxan ? herceptin ? pertuzumab (FEC ? H ? P)X3 ? docetaxel (T) ? H ? PX3 (arm A); FEC ? T ? H ? PX3 (arm B); and T ? carboplatin ? H ? P (arm C). The incidence of significant LVEF decline to [10 % below baseline or \50 % was low in all three arms (arm A 5.6 %, arm B 5.3 %, arm C 3.9 %) [51] . The currently enrolling BERENICE trial (National Science Foundation Census research Work 3113) is a multi-center phase II trial evaluating the cardiac safety of AC followed by THP in the neoadjuvant setting in locally advanced, inflammatory, or early-stage HER2-positive breast cancer.
Trastuzumab Emtansine
Trastuzumab emtansine (Kadcyla Ò ) is an antibody drug conjugate directed at the domain IV of extracellular domain of HER2. It consists of a microtubule inhibitor maytansine, conjugated to trastuzumab via a thioether linker. Kadcyla Ò is approved for use in HER2-positive metastatic breast cancer in both the second-line and the third-line setting as per the EMILIA and TH3RESA trials, respectively [52, 53] . The median age of patients enrolled in both these trials was much younger, and definite studies have not been conducted in older patients. However, in both these phase III trials, the drop of LVEF \50 % or [15 % of baseline value occurred in 1.7 and 1 % of patients, respectively.
In a recently published feasibility study, trastuzumab emtansine was administered for a period of 1 year after adjuvant or neoadjuvant chemotherapy with an anthracycline-based regimen in HER2-positive early breast cancer. Only 11.8 % of the 153 patients were aged [65 years. Only 2.7 % of the patients experienced asymptomatic decline in LVEF by [10 percentage points of \50 % [17] . This is a favorable cardiac safety profile compared with the published trastuzumab trials [14, 40] .
Based on encouraging clinical data on efficacy, and the favorable toxicity profile of Kadcyla Ò in an adjuvant setting, the ongoing phase II ATEMPT trial (NCT01853748) compares a paclitaxel and herceptin regimen to Kadcyla Ò in early-stage, node-negative, HER2-positive breast cancer.
The favorable toxicity profile of Kadcyla Ò makes it an attractive option for use in elderly patients.
Lapatinib
Lapatinib is a dual HER1/HER2-blocking agent approved for use in combination with capecitabine in patients with HER2-positive metastatic breast cancer who have already received anthracycline, taxane, and trastuzumab [54] . The efficacy and safety of this combination was evaluated in an elderly population in a small retrospective multicenter study of 26 patients. The median age was 69 years (range 65-82). Median follow-up was 10 months. The ORR was 33.4 %, with one complete response. Median PFS was 7 months (95 % CI 5-8), and OS was 15 months (95 % CI [11] [12] [13] [14] [15] [16] [17] [18] [19] . Grade 3 and 4 toxicities included diarrhea (7.6 %), hand-foot syndrome (3.8 %), and fatigue (11.5 %) . No cardiac toxicities were reported [55] .
The recently reported NEOALTTO trial, adding lapatinib to trastuzumab and paclitaxel, improved pathological complete response (pCR) rates in the neoadjuvant setting compared with paclitaxel/trastuzumab, paclitaxel/lapatinib. However, there was no difference in event-free survival or OS [56] .
Based on the encouraging results of the NEOALTTO trial, the ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) trial was a phase III trial in 8381 patients; it was designed to compare three regimens of oral lapatinib (T ? L, L alone or T ? L) to T alone. The L ? T arm was tested against T for superiority and the T ? L arm was tested for non-inferiority. The DFS improvement was non-statistically significant in both arms. The HR for DFS was 0.84 (97.5 % CI 0.70-1.02; p = 0.048; 4-year DFS = 88 % vs. 86 %) for L ? T versus T and 0.93 (97.5 % CI 0.76-1.13; non-inferiority; p = 0.044; 4-year DFS = 87 vs. 86 %) for T ? L vs. T. This was a disappointing observation, given that near doubling of pCR rates was observed with dual T ? L blockade in the neoadjuvant setting [57] .
Lapatinib was initially reported to have no cardiotoxicity [58] , but subsequent reports revealed a low incidence of cardiac toxicity, which is reversible in nature [33] . One of the suggested mechanisms of heart toxicity with lapatinib is lack of specificity to kinase inhibition, which could result in on-target and off-target collateral effects, leading to myocyte damage [59] . In a comprehensive analysis of 3689 lapatinib-treated patients enrolled in 49 trials, asymptomatic cardiac events were reported in 53 patients (1.4 %), and symptomatic grade III and IV systolic dysfunction was observed only in seven patients (0.2 %) [60] .
Phosphatidyl Inositol 3 Kinase (PI3K) Inhibitors
Although trastuzumab is highly efficacious in metastatic HER2-positive breast cancer, most patients eventually progress due to the development of secondary resistance. Activation of the PI3/protein kinase B/mammalian target of rapamycin (PI3/AKT/mTOR) pathway is thought to be one of the resistance mechanisms to trastuzumab. Everolimus is an mTOR inhibitor that has been shown to potentiate the activity of trastuzumab in phase I and II studies [61] [62] [63] . In the BOLERO (Breast Cancer trials of OraL EveROlimus)-3 trial, 569 patients with metastatic HER2-positive breast cancer were treated with vinorelbine and trastuzumab plus placebo versus everolimus. The everolimus-treated group significantly prolonged PFS (7 vs. 5.78 months, HR 0.78; 95 % CI 0.65-0.95, p = 0.0067). However, there were significantly higher grade 3/4 toxicities in the everolimus group [64] . Although 19 % of the patients receiving everolimus were aged [65 years, the toxicities have not yet been stratified according to age. However, in the BOLERO-2 study, which investigated everolimus ? exemestane compared with exemestane alone for metastatic hormone-positive breast cancer, the elderly age group had the same incidence of frequency of dose modifications due to adverse events, regardless of age. The incidence of headache, stomatitis, rash, nail changes, hypercholesterolemia, and elevated hepatic enzymes was lower in the elderly age group [65] . However, there is a concern for increasing toxicity when everolimus is used in elderly patients due to its metabolism via the cytochrome P450 pathway and the presence of polypharmacy in this population.
Conclusion
With increasing life expectancies, the number of older patients with breast cancer will rise. Since the addition of HER2-directed therapy has shown improvement in survival when used in elderly patients in both adjuvant and metastatic settings, chronological age should not be a determinant of who gets HER2-directed therapy. Instead, functional parameters such as performance status and geriatric assessment tools should be used to determine who should be offered HER2-directed therapy. Every effort should be exercised to reduce cardiac toxicity by exclusion of patients with significant cardiac risk factors and by optimizing cardiac parameters.
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